Neuronoff, Inc.

Neuronoff, Inc. is a medical device company based in Cleveland, Ohio, focused on developing minimally invasive neuromodulation solutions. The company's primary product is the Injectrode® platform, designed to treat chronic pain without the use of drugs, opioids, surgery, or scars. This innovative device is injected under the skin to target specific nerves, blocking pain signals electrically and offering a fully reversible and suture-free alternative to traditional pain management methods.

Founded to simplify neuromodulation therapies, Neuronoff aims to improve access to treatment for chronic pain patients, physicians, and healthcare providers. The company has recently completed first-in-human trials, demonstrating the safety and functionality of the Injectrode. With plans for FDA clearance in 2026, Neuronoff is advancing its development pipeline to address various conditions, including autonomic, bladder, cardiac, and inflammatory disorders. The company is led by CEO Manfred Franke and has recently secured $4.5 million in funding to support the launch of the Injectrode platform.